Cogent Biosciences, Inc. (COGT) — Stock Price, Chart & Analysis
Cogent Biosciences, Inc. (COGT) is a Healthcare stock currently trading at $42.39, up 1.41% on the day. It carries a market capitalization of $7.24B. Over the past 52 weeks, COGT has traded between $10.72 and $43.73. Cogent Biosciences, Inc. does not currently pay a regular dividend. View the live COGT chart, technical opinion, analyst ratings, fundamentals and latest news below.
Cogent Biosciences, Inc. (COGT) key data
| Price | $42.39 |
| Change (today) | +1.41% |
| Previous close | $41.8 |
| Market cap | $7.24B |
| EPS (TTM) | $-2.17 |
| 52-week high | $43.73 |
| 52-week low | $10.72 |
| Beta | 0.33 |
| Avg. volume | 2.49M |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently asked questions about Cogent Biosciences, Inc. (COGT)
How much does one share of Cogent Biosciences, Inc. cost?
As of the latest update, one share of Cogent Biosciences, Inc. (COGT) trades at $42.39 (+1.41% today).
What is Cogent Biosciences, Inc.'s market cap?
Cogent Biosciences, Inc. has a market capitalization of approximately $7.24B.
What is Cogent Biosciences, Inc.'s earnings per share (EPS)?
Cogent Biosciences, Inc.'s trailing twelve-month EPS is $-2.17.
Does Cogent Biosciences, Inc. pay a dividend?
Cogent Biosciences, Inc. does not currently pay a regular dividend.
What is Cogent Biosciences, Inc.'s 52-week trading range?
Over the past year, COGT has traded between $10.72 and $43.73.
What is the analyst price target for Cogent Biosciences, Inc.?
The mean analyst price target for Cogent Biosciences, Inc. is $54.25. This is informational only and not investment advice.
Latest Cogent Biosciences, Inc. (COGT) news
- Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)News · Jun 30, 2026
- Is Cogent Biosciences (COGT) ’s New Cancer Drug 100 Times More Precise Than What’s Already on the Market?News · Jun 22, 2026
- Cogent Biosciences' Potential Rare Blood Disease Treatment Meets Endpoints in Clinical TrialNews · Jun 12, 2026
- Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) CongressNews · Jun 12, 2026
- Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) CongressNews · Jun 12, 2026
- How Investors May Respond To Cogent Biosciences (COGT) Priority Review For Bezuclastinib GIST RegimenNews · Jun 10, 2026
Headlines via Yahoo Finance and publishers — click through to read each story at its source.
Loading the live COGT dashboard…